Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

Completed · Phase 2

Conditions studied: Melanoma (Skin)

In brief

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Giving the vaccine with interleukin-2 or sargramostim may help kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of peptide vaccine with or without adjuvant interleukin-2 or sargramostim in treating patients who have recurrent or refractory metastatic melanoma.

Key facts

Study ID

NCT00019383

Run by

National Cancer Institute (NCI)

Starts

1998-01-01

Expected to finish

2003-06-01

Last updated by the study team

2013-06-20

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Surgery Branch — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.